Understanding the role of GABA C receptors in the central nervous system is limited due to a lack of specific ligands. Novel γ-aminobutyric acid (GABA) analogues based on 3-(aminomethyl)-1-oxo-1-hydroxy-phospholane 17 and 3-(guanido)-1-oxo-1-hydroxy-phospholane 19 were investigated to obtain selective GABA C receptor antagonists. A compound of high potency (19, K B =10 μM) and selectivity (greater than 100 times at F 1 GABA C receptors as compared to R 1 β 2 γ 2L GABA A and GABA B(1b,2) receptors) was obtained. The cyclic phosphinic acids (17 and 19) are novel lead agents for developing into more potent and selective GABA C receptor antagonists with increased lipophilicity for future in vivo studies.